These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis. Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439 [TBL] [Abstract][Full Text] [Related]
6. Serum levels of soluble CD95 are not associated with amelioration of multiple sclerosis during pregnancy. Ehrlich S; Haas J; Zipp F; Infante-Duarte C J Neurol Sci; 2007 Jan; 252(1):83-7. PubMed ID: 17169375 [TBL] [Abstract][Full Text] [Related]
7. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study. Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466 [TBL] [Abstract][Full Text] [Related]
8. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S; Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883 [TBL] [Abstract][Full Text] [Related]
9. Level of sFas/APO 1 in serum and cerebrospinal fluid in multiple sclerosis. Mahovic D; Petravic D; Petelin Z; Zurak N; Horvat G; Hajnsek S Clin Neurol Neurosurg; 2004 Jun; 106(3):230-2. PubMed ID: 15177773 [TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta. Boz C; Ozmenoglu M; Velioglu S; Kilinc K; Orem A; Alioglu Z; Altunayoglu V Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833 [TBL] [Abstract][Full Text] [Related]
12. Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy. Fainardi E; Rizzo R; Melchiorri L; Castellazzi M; Govoni V; Caniatti L; Paolino E; Tola MR; Granieri E; Baricordi OR J Neuroimmunol; 2004 Mar; 148(1-2):206-11. PubMed ID: 14975603 [TBL] [Abstract][Full Text] [Related]
13. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Schwid SR; Panitch HS Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202 [TBL] [Abstract][Full Text] [Related]
14. [Interferon therapy of multiple sclerosis]. Jensen D Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3142-5. PubMed ID: 10522481 [TBL] [Abstract][Full Text] [Related]